Urokinase biosimilar - Cerbios-Pharma

Drug Profile

Urokinase biosimilar - Cerbios-Pharma

Alternative Names: HMW tc-uPA - Cerbios-Pharma; HMW-UK - Cerbios-Pharma; Recombinant human two chain high molecular weight urokinase - Cerbios-Pharma; Recombinant human urinary type plasminogen activator - Cerbios-Pharma; Recombinant urokinase - Cerbios-Pharma

Latest Information Update: 06 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cerbios-Pharma
  • Class Granulocyte colony-stimulating factors; Plasminogen activator enzymes; Recombinant fusion proteins; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Vascular disorders

Most Recent Events

  • 06 May 2015 Cerbios-Pharma has patent protection for Recombinant urokinase (Cerbios-Pharma website, May 2015)
  • 06 May 2015 Preclinical trials in Vascular disorders in Switzerland (unspecified route) (Cerbios-Pharma website, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top